BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Nektar Therapeutics will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-based financial markets.

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Ontario Drug Benefit Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

Acadia Pharmaceuticals Inc. announced that on July 18, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 19,903 shares of common stock and 11,988 restricted stock units to 16 new employees under Acadia’s 2023 Inducement Plan.

Tarsus Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 5,714,285 shares of its common stock at a public offering price of $17.50 per share, before underwriting discounts and commissions.

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of July 31, 2023, grants of non-qualified stock options to purchase an aggregate of 20,600 shares of its common stock and restricted stock units covering 10,300 shares of its common stock under the Inducement Plan to two new employees.

Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, announced that it will publish financial results for the second quarter 2023 and provide a business update on August 4, 2023.

Bioventus Inc., a global leader in innovations for active healing, announced that it will report financial results for the second quarter of fiscal year 2023 before the market opens on Tuesday, August 8, 2023.

PROCEPT BioRobotics® Corporation announced the pricing of an upsized underwritten public offering of 4,422,169 shares of its common stock at a public offering price of $33.92 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $150 million.

Aptevo Therapeutics Inc. announced that the Company has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of 8,064,517 shares of common stock at a purchase price of $0.62 per share.